<DOC>
	<DOCNO>NCT01712061</DOCNO>
	<brief_summary>The study hypothesis test administration CCR2/5 antagonist subject type 2 diabetes overt nephropathy result reduction urinary albumin , surrogate improve glomerular filtration .</brief_summary>
	<brief_title>A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Clinical diagnosis type 2 diabetes together stage 2 , 3a , 3b 4 CKD , base eGFR 2075 mL/min/1.73m2 . Evidence persistent , overt albuminuria ; define UACR &gt; =300 mg/g ( &gt; =33.9 mg/mmol ) UPCR &gt; =390 mg/g ( 44.1 mg/mmol ) , equivalent , 3 month longer . Stable background therapy RAAS inhibition ( ie , ACE inhibitor and/or ARB , may also include aldosterone antagonist double RAAS triple RAAS inhibitor therapy ) least 3 month screen maintain duration study . Subjects CKD result type 1 diabetes nondiabetic CKD . Subjects diagnose autosomal dominant polycystic kidney disease ( ADPCKD ) , severe peripheral vascular disease ( PVD ) obstructive uropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>albuminuria</keyword>
	<keyword>chemokine antagonist</keyword>
</DOC>